Background: Antibiotics are frequently used to treat hidradenitis suppurativa (HS); however, few data on their efficacy are available. Objective: To evaluate the efficacy of a combination of systemic clindamycin (300 mg twice daily) and rifampicin (600 mg daily) in the treatment of patients with severe HS. Methods: Patients (n = 116) who received this combination were studied retrospectively. The main outcome measure was the severity of the disease, assessed by the Sartorius score, before and after 10 weeks of treatment. Results: The Sartorius score dramatically improved at the end of treatment (median = 29, interquartile range = 14.5, vs. median = 14.5, interquartile range = 11; p < 0.001), as did other parameters of severity as well as the quality of life score. Eight patients (6.9%) stopped the treatment because of side effects. Conclusion: The combination of clindamycin and rifampicin is effective in the treatment of severe HS.

Keywords:
Hidradenitis suppurativa, Rifampicin, Clindamycin, Sartorius score, Quality of life
1.
Jemec GBE, Heidenheim M, Nielsen NH: The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996;35:191–194.
2.
Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al: Prevalence and factors associated with hidradenitis suppurativa: a case control study. J Am Acad Dermatol 2008;59:596–601.
3.
Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J: Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007;56:621–623.
4.
Jemec GBE, Heidenheim M, Nielsen NH: Hidradenitis suppurativa. Cutan Med Surg 2003;7:47–56.
5.
Brook I, Frazier EH: Aerobic and anaerobic microbiology of axillary hidradenitis suppurativa. J Med Microbiol 1999;48:103–105.
6.
Jemec GBE, Faber M, Gutschik E, Wendelboe P: The bacteriology of hidradenitis suppurativa. Dermatology 1996;193:203–206.
7.
Leach RD, Eykyn SJ, Phillips I, et al: Anaerobic axillary abscess. Br Med J 1979;2:5–7.
8.
Oprica C, Nord CE: Bacteriology of hidradenitis suppurativa; in Jemec GBE, Revuz J, Leyden JJ (ed): Hidradenitis Suppurativa. Berlin, Springer, 2006.
9.
Lapins J, Jarstrand C, Emtestam L: Coagulase negative staphylococci are the most common bacteria founding culture from deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 1999;140:90–95.
10.
Brooke RC, Griffiths C: Folliculitis decalvans. Clin Exp Dermatol 2001;26:120–122.
11.
Mendonça CO, Griffiths CE: Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol 2006;154:977–978.
12.
Sartorius K, Lapins J, Emtestam L, Jemec GB: Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa. Br J Dermatol 2003;149:211–213.
13.
Revuz J: Modifications et mode d’emploi du score de Sartorius pour évaluer la gravité de l’hidradénite suppurée. Ann Dermatol Venereol 2007;134:173–174.
14.
Hurley HJ: Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach; in Roenigk RK, Roenigk HH, (eds): Dermatologic Surgery. New York, Dekker, 1989, pp 729–739.
15.
Van der Zee HH, Boer J, Prens EP, Jemec GBE: The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 2009;219:143–147.
16.
Canoui-Poitrine F, Revuz J, Wolkenstein P, Viallette C, Gabison G, Pouget F, Poli F, Faye O, Bastuji-Garin S: Clinical characteristics of a series of 302 French patients suffering from hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009, in press.
17.
Von der Werth JM, Jemec GBE: Morbidity in patients with hidradenitis suppurativa. Br J Dermatol 2001;144:809–813.
18.
Jemec GBE, Heidenheim M, Nielsen NH: Hidradenitis suppurativa – characteristics and consequences. Clin Exp Dermatol 1996;21:419–423.
19.
Tsankov N, Angelova I: Rifampicin in dermatology. Clin Dermatol 2003;21:50–55.
20.
Arditi M, Yogev R: In vitro interaction between rifampin and clindamycin against pathogenic coagulase-negative staphylococci. Antimicrob Agents Chemother 1989;33:245–247.
21.
Spizek J, Rezanka T: Lincomycin, clindamycin and their applications. Appl Microbiol Biotechnol 2004;64:455–464.
22.
Clemmensen OJ: Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983;22:325–328.
23.
Jemec GB, Wendelboe P: Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998;39:971–974.
24.
Schlievert PM, Kelly JA: Clindamycin-induced suppression of toxic-shock syndrome-associated exotoxin production. J Infect Dis 1984;149:471.
25.
Wijaya A, Wulansari R, Ano H, Makimura S: Effect of clindamycin therapy on phagocytic and oxidative activity profiles of spleen mononuclear cells in Babesia rodhaini-infected mice. J Vet Med Sci 2001;63:563–566.
26.
Spisani S, Traniello S, Martuccio C, Rizzuti O, Cellai L: Rifamycins inhibit human neutrophil functions: new derivatives with potential antiinflammatory activity. Inflammation 1997;21:391–400.
27.
Liu XG, Narang PK, Li RC: Induction of hepatic and presystemic metabolism of antipyrine in the mice: rifampicin versus rifabutin. Eur J Drug Metab Pharmacokinet 2001;26:209–213.
28.
Yerramasetti R, Gollapudi S, Gupta S: Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J Clin Immunol 2002;22:37–47.
29.
Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS: Infliximab for hidradenitis suppurativa. Br J Dermatol 2003;149:1046–1049.
30.
Moschella SL: Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol 2007;46:1287–1291.
31.
Mekkes JR, Bos JD: Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008;158:370–374.
32.
Fernández-Vozmediano JM, Armario-Hita JC: Infliximab for the treatment of hidradenitis suppurativa. Dermatology 2007;215:41–44.
33.
Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, Bachelez H, Morel P, Lebbé C: Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007;56:624–628.
34.
Thielen AM, Barde C, Saurat JH: Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol 2006;155:1105–1107.
35.
Cusack C, Buckley C: Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 2006;154:726–729.
36.
Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, Petropoulou H, Baziaka F, Karagianni V, Stavrianeas N, Giamarellou H: An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 2008;158:567–572.
37.
Scheinfeld N: Treatment of coincident seronegative arthritis and hidradenitis suppurativa with adalimumab. J Am Acad Dermatol 2006;55:163–164.
38.
Moul DK, Korman NJ: The cutting edge: severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol 2006;142:1110–1112.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.